Home / Business / Trump urges regulators to approve emergency clearances for antibody treatments Regeneron, Eli Lilly COVID-19

Trump urges regulators to approve emergency clearances for antibody treatments Regeneron, Eli Lilly COVID-19



President Trump urged regulators Wednesday evening in a video message on Twitter to approve an emergency use permit for Regeneron and Eli Lilly’s antibody treatments.

Trump specifically advertised Regeneron’s antibody cocktail as a key aspect of his treatment, likening it to a “cure” rather than a therapeutic treatment.

“We have hundreds of thousands of doses that are almost ready,”

; Trump said. “I have all the emergency use permissions set and we need to get it signed now. And you will improve, you will improve very quickly.”

EXPERIMENTAL CHINESE VACCINE AGAINST COROANVIRUS REPORTED SAFE IN THE FIRST TESTS PHASE: RESEARCHERS

The announcement comes after the president was discharged from Walter Reed National Military Medical Center on Monday after being treated for the coronavirus.

President Donald Trump gives the thumbs up as he returns to the White House on Monday, October 5, 2020 in Washington, after leaving Walter Reed National Military Medical Center, in Bethesda, Md. Trump announced he tested positive for COVID-19 in October. 2. (AP P

According to a declaration On Friday, White House press secretary Kayleigh McEnany received an 8-gram dose of the REGN-COV2 polyclonal antibody cocktail through “compassionate use,” which makes experimental drugs available to people outside of clinical trials.

McEnany’s statement also mentioned that the president took “zinc, vitamin D, famotidine, melatonin and a daily aspirin”.

REGENERON HAS TRUMP’S COVID-19 TREATMENT: WHAT TO KNOW

Regeneron CEO Dr. Leonard Schleifer told Fox News earlier this week that the company was working to obtain an extended authorization for emergency use for the experimental treatment.

“I don’t know how long it will take,” he added. “We are working with the FDA, we believe we meet the criteria.”

Meanwhile, Eli Lilly announced Wednesday that it has filed its emergency use authorization application for its LY-CoV555 monotherapy. The company said it expects to be able to supply up to 100,000 doses by the end of October and up to 1 million by next year.

“We plan to submit a subsequent EUA application for combination therapy in November pending enrollment in the clinical trial once we have accumulated additional safety data and sufficient supply,” the company added. “Lilly expects to have data to support the submission of a biologic licensing application for combination therapy already [the second quarter of] 2021. Conversations are ongoing with global regulators. “

CLICK HERE TO READ MORE FOX BUSINESS STORIES

Trump added that the administration intends to make Regeneron and Eli Lilly’s treatments free for patients with the virus, especially the elderly.

“If you are in the hospital and you feel really bad, I think we will work so that you take them and set them free,” Trump said. “Especially if you are an elder, we will let you in soon.”

He also noted that the military will manage the logistics for distributing the treatments, claiming they could potentially deliver “hundreds of thousands of doses” within days.

“We’re waiting for emergency use clearance and drug companies have done a lot of it,” added Trump. “So I hope this will not just be a therapeutic, it will be much more than a therapeutic. You will improve, you will improve quickly. Just like I did.”

Ticker Safety Last Modify Modify %
REGN REGENERON PHARMACEUTICALS INC. 591.69 +10.05 + 1.73%
LLY ELI LILLY & COMPANY 148.96 +4.83 + 3.35%

Stocks in Regeneron were up nearly 4% in over-hours trading on Wednesday, while Eli Lilly was up nearly 2% in over-hours trading.

GET BUSINESS FOX ON THE GO BY CLICKING HERE




Source link